Skip to content
SCTE Logo SCTE Logo
  • Home
  • About Us
  • Services
    • Clinical Trials Brochure
  • Media & Events
  • Clinical Trials Volunteers
  • Clinical Investigators
  • Partnerships
  • Contact Us
XPhoneEmail
+966 (11) 429-4516
SCTE@ngha.med.sa

Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial

  1. Home
  2. Events
  3. Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial
Previous Next
  • View Larger Image

Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial

More Information
MutairiF982021-11-29T06:32:41+00:00
© Copyright      |    All Rights Reserved to KAIMRC
XPhoneEmail
Page load link
Go to Top